These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 36977465)

  • 21. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metal-based strategies for the fight against COVID-19.
    Li H; Yuan S; Wei X; Sun H
    Chem Commun (Camb); 2022 Jul; 58(54):7466-7482. PubMed ID: 35730442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2.
    Hu Y; Liu L; Zhang S; Su S; Liang X
    ACS Omega; 2024 Feb; 9(5):5175-5192. PubMed ID: 38343922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronavirus disease 2019: A tissue engineering and regenerative medicine perspective.
    Shafiee A; Moradi L; Lim M; Brown J
    Stem Cells Transl Med; 2021 Jan; 10(1):27-38. PubMed ID: 32820868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Nutrients in Prevention, Treatment and Post-Coronavirus Disease-2019 (COVID-19).
    Motti ML; Tafuri D; Donini L; Masucci MT; De Falco V; Mazzeo F
    Nutrients; 2022 Feb; 14(5):. PubMed ID: 35267974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early protective effect of a ("pan") coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration.
    Abdelaziz MO; Raftery MJ; Weihs J; Bielawski O; Edel R; Köppke J; Vladimirova D; Adler JM; Firsching T; Voß A; Gruber AD; Hummel LV; Fernandez Munoz I; Müller-Marquardt F; Willimsky G; Elleboudy NS; Trimpert J; Schönrich G
    Front Immunol; 2023; 14():1166765. PubMed ID: 37520530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.
    Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection: Microbiologic perspectives and anatomic considerations for sanctuary sites.
    Azu OO; Olojede SO; Lawal SK; Oseni SO; Rennie CO; Offo U; Naidu ECS
    J Infect Public Health; 2021 Sep; 14(9):1237-1246. PubMed ID: 34455307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
    Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR
    Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The novel zoonotic COVID-19 pandemic: An expected global health concern.
    Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
    J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
    Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smart Nanostructured Materials for SARS-CoV-2 and Variants Prevention, Biosensing and Vaccination.
    Wang L; Li Z
    Biosensors (Basel); 2022 Dec; 12(12):. PubMed ID: 36551096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coronaviruses: What Should We Know About the Characteristics of Viruses?
    Ji W
    Adv Exp Med Biol; 2021; 1318():23-39. PubMed ID: 33973170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19.
    Majolo F; da Silva GL; Vieira L; Timmers LFSM; Laufer S; Goettert MI
    Stem Cell Rev Rep; 2021 Feb; 17(1):44-55. PubMed ID: 32827081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.
    Ghasemiyeh P; Mohammadi-Samani S; Firouzabadi N; Dehshahri A; Vazin A
    Int Immunopharmacol; 2021 Nov; 100():108162. PubMed ID: 34562844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
    Jiang L; Driedonks TAP; Jong WSP; Dhakal S; Bart van den Berg van Saparoea H; Sitaras I; Zhou R; Caputo C; Littlefield K; Lowman M; Chen M; Lima G; Gololobova O; Smith B; Mahairaki V; Riley Richardson M; Mulka KR; Lane AP; Klein SL; Pekosz A; Brayton C; Mankowski JL; Luirink J; Villano JS; Witwer KW
    J Extracell Vesicles; 2022 Mar; 11(3):e12192. PubMed ID: 35289114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Epidemiology, Treatment, and Epidemic Prevention and Control of the Coronavirus Disease 2019: a Review].
    Luan RS; Wang X; Sun X; Chen XS; Zhou T; Liu QH; Lü X; Wu XP; Gu DQ; Tang MS; Cui HJ; Shan XF; Ouyang J; Zhang B; Zhang W; Sichuan University Covid- ERG
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 51(2):131-138. PubMed ID: 32220177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aptamer-Mediated Antiviral Approaches for SARS-CoV-2.
    Tan KX; Jeevanandam J; Rodrigues J; Danquah MK
    Front Biosci (Landmark Ed); 2022 Nov; 27(11):306. PubMed ID: 36472112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.